ECTRIMS 2022 | Spinal cord atrophy: an imaging biomarker in multiple sclerosis

Spinal muscular atrophy has a robust correlation with clinical disabilities and progression in multiple sclerosis (MS). Burcu Zeydan, MD, Mayo Clinic, Rochester, MN, provides an overview of spinal cord atrophy (SCA) as a potential imaging biomarker of subclinical progression in MS. This concept was investigated in a spinal cord MRI study conducted in 2017, where patients with secondary progressive MS (SPMS) within one year of progressive MS onset were compared with patients having radiologically isolated syndrome (RIS) and relapsing-remitting MS (RRMS). It was observed that SPMS patients had lower spinal cord volume when compared with subjects of RIS and RRMS. Thus, this study confirmed the use of SCA as an imaging biomarker in MS. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2022 in Amsterdam, The Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.